The proteasome: structure, function, and role in the cell.

[1]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[2]  R. Meyn,et al.  Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells , 2001, International journal of cancer.

[3]  P. Elliott,et al.  Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. , 2001 .

[4]  D. W. Kim,et al.  Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance , 2001, Oncogene.

[5]  R. Bold,et al.  Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. , 2001, The Journal of surgical research.

[6]  R. Huber,et al.  Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. , 2001, Journal of molecular biology.

[7]  Wei Ping Wang,et al.  Inhibition of proteasome function induced apoptosis in gastric cancer , 2001 .

[8]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[9]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[10]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[12]  D. Delia,et al.  The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI , 2001, British journal of haematology.

[13]  C. Watson,et al.  p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells , 2001, Cell Death and Differentiation.

[14]  Steffen Hauptmann,et al.  Proteasome inhibitors induce caspase‐dependent apoptosis and accumulationof p21WAF1/Cip1 in human immatureleukemic cells , 2000 .

[15]  P. Elliott,et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[17]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[18]  C. Gélinas,et al.  The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL , 2000, Molecular and Cellular Biology.

[19]  Yulian Wu,et al.  The proteasome controls the expression of a proliferation‐associated nuclear antigen Ki‐67 , 2000, Journal of cellular biochemistry.

[20]  C. Scheidereit,et al.  Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells , 2000, Leukemia.

[21]  S. Sato,et al.  p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  G. Tricot.  New insights into role of microenvironment in multiple myeloma , 2000, The Lancet.

[23]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[24]  H. Magdelenat,et al.  Ubiquitin-Proteasome System and Increased Sensitivity of B-CLL Lymphocytes to Apoptotic Death Activation , 2000, Leukemia & lymphoma.

[25]  K. Wilkinson.  Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment. , 1999, The Journal of nutrition.

[26]  W. Baumeister,et al.  The proteasome: a macromolecular assembly designed for controlled proteolysis. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[27]  Marty W. Mayo,et al.  NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.

[28]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Crews,et al.  Eponemycin exerts its antitumor effect through the inhibition of proteasome function. , 1999, Cancer research.

[30]  S Omura,et al.  Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin , 1999, British journal of haematology.

[31]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[32]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[33]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[34]  W Keilholz,et al.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[36]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[37]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[38]  S. Ōmura,et al.  The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. , 1998, British Journal of Cancer.

[39]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[40]  A. Goldberg,et al.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Dick,et al.  Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin , 1996, The Journal of Biological Chemistry.

[42]  K. Tanaka,et al.  Abnormally high expression of proteasomes in human leukemic cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[44]  P. Elliott,et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. , 2001, International journal of radiation oncology, biology, physics.

[45]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.